Global Antiretroviral Drugs Market Report 2019: Analysis By

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
36
Global Antiretroviral Drugs Market Report 2019: Analysis By Drug Type, Region & Drug Forecast 2013-2023

Dublin, April 09, 2019 (GLOBE NEWSWIRE) -- The "Global Antiretroviral Drugs Market: Analysis By Drug Type, By Region, By Country, Drug Forecast (2019 Edition): Opportunities and Forecast (2013-2023)" report has been added to ResearchAndMarkets.com's offering. Global antiretroviral market is projected to display a robust growth represented by a CAGR of 4.70% during 2018-2023 Over the recent years, Antiretroviral drugs market has been witnessing growth on account of several driving factors including growing prevalence of HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs with better efficacy. Moreover, factors such as growing medical spending, favorable steps by government of various countries, decreased cost of treatment, improved diagnosis rate, and rise in the favorable programs to provide diagnosis and treatment facilities to the unmet patient population has been driving the market growth of antiretroviral drugs. In addition, increasing uptake of INSTI based regimens, increasing awareness regarding HIV care and treatment procedures, new drug launches, and improved R&D pipeline are anticipated to fuel the market growth in forecasted period. However, growing portfolio of generic antiretroviral drugs is expected impact the overall market growth. In this research report, the market is segmented on the basis of drug type. By drug type, the multi-class drug combinations are predicted to hold their dominant position in the market, especially Gilead Sciences product Biktarvy and ViiV Healthcare product Triumeq are expected to give more traction to the market. Amongst the regions, North America accounts for the largest regional share in the global antiretroviral market in 2017. The largest share of North America is attributed to high ART coverage rate and more emphasis towards prescribed branded drugs. Key Topics Covered: 1. Research Methodology 2. Executive Summary 3. Strategic Recommendations 4. Antiretroviral Drugs Products Outlook 5. Global Antiretroviral Drugs Market: Growth and Forecast 5.1 By Value (2013-2017) 5.2 By Value (2018-2023) 6. Global Antiretroviral Drugs Market: Segment Analysis 6.1 Global Antiretroviral Drugs Market Size, By Drug Type: Breakdown (%) 6.2 Global Multi-Class Drugs Combination Market Size, By Value (2013-2023) 6.3 Global NRTI Market Size, By Value (2013-2023) 6.4 Global NNRTI Market Size, By Value (2013-2023) 6.5 Global Protease Inhibitors Market Size, By Value (2013-2023) 6.6 Global Other Antiretroviral Drugs Market Size, By Value (2013-2023) 6.6 Global Antiretroviral Drugs: Market Attractiveness, By Drug Type 6.7 Global Market: Drugs Forecast (Multi-Class Drugs Combination, NRTI, NNRTI, Protease Inhibitors, CCR5) 7. Global Antiretroviral Drugs Market: Regional Analysis 7.1 Global Antiretroviral Drugs Market Size, By Region: Breakdown (%) 7.1.1 Global Antiretroviral Drugs Market Size, By Region, 2017 (%) 7.1.2 Global Antiretroviral Drugs Market Size, By Region, 2023 (%) 8. North America Antiretroviral Drugs Market: Growth and Forecast 9. Europe Antiretroviral Drugs Market: Growth and Forecast 10. APAC Antiretroviral Drugs Market: Growth and Forecast 11. ROW Antiretroviral Drugs Market: Growth and Forecast 12. Global Antiretroviral Drugs Market: Market Dynamics 12.1 Global Antiretroviral Drugs Market: Drivers 12.2 Global Antiretroviral Drugs Market: Restrains 12.3 Global Antiretroviral Drugs Market: Trends 12.4 Global Antiretroviral Drugs Market: Product Benchmarking 13. Porter Five Force Analysis 14. SWOT Analysis 15. Company Profiles

  • Gilead Sciences Inc.
  • ViiV Healthcare
  • Bristol-Myers Squibb
  • AbbVie Inc.
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Merck & Co.
  • Cipla
  • Mylan

For more information about this report visit https://www.researchandmarkets.com/r/yapm48

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI and Workforce Transformation: Zellis Connect 2026

Updated Category News Views 2

AI Transformation: Hard Reality or Strategic Opportunity? The future of work. That’s what everyone’s buzzing about lately, isn’t it? AI poised to shake every nook and cranny. You're either riding the wave or getting crushed by it. It’s no longer some distant prospect—the challenge is right here, now. Come September 23, Zellis Connect 2026 is plunging headfirst...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 4

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Early Orders Key for Custom Kids' Gifts This Season

Updated Category News Views 0

Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...

Continue Reading
Nuix Leverages AI for Transformative Legal Review

Updated Category News Views 1

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Continue Reading
XiamenAir Takes Off with Fujian-London Link

Updated Category News Views 3

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Continue Reading
BYD's Chip Mastery Amid China's Auto Supply Tensions

Updated Category News Views 7

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

Continue Reading
PBC 2026 Forum: Philanthropic Titans Collide in HK

Updated Category News Views 0

A Decade of Philanthropic Discourse The winds of change blew through Hong Kong’s West Kowloon Cultural District today, marking the tenth anniversary of the PBC 2026 forum—an event that’s got everyone from government bigwigs to sports icons chatting. Convened by The Hong Kong Jockey Club Charities Trust alongside the Institute of Philanthropy, this two-day journey is...

Continue Reading
SKF's Automotive Arm Set for Stockholm Debut in Dec

Updated Category News Views 0

The Big Spin-Off Play: SKF Vertevo So, SKF is at it again, pushing their Automotive business out the door as a newly minted public company—SKF Vertevo—on the horizon. It's like watching a mother bird kick the fledgling out of the nest. The Board's cooked up this spin-off strategy, and they're eyeing the Nasdaq Stockholm as the breeding ground, with the gears all set...

Continue Reading
La Compagnie Unveils NYC-Düsseldorf Flight Plans

Updated Category News Views 2

A new chapter is unfolding in the skies over the Atlantic. La Compagnie is gearing up to connect New York to Düsseldorf with a direct, all-business-class flight starting in Spring 2027. This move is ambitious, tapping into the bustling economic energy present across the North Rhine-Westphalia region—an economic powerhouse littered with U.S.-affiliated businesses. A...

Continue Reading
Lyon Biennale 2026: Art, Dreams, and Lyon's Magic

Updated Category News Views 0

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Continue Reading

Top 5 Most Recently Viewed Articles

HFCL's Eka™ Fiber Revolutionizes Telecom Connectivity in Europe

Updated Category News Views 150

HFCL Launches Eka™ Fiber at the FTTH Conference 2025 HFCL Limited, a global pioneer in next-generation telecommunications solutions, has unveiled its innovative Eka™ Optical Fiber at the FTTH Conference 2025. Designed in collaboration with European telecom companies, this groundbreaking fiber aims to bridge the connectivity gaps within rural and urban landscapes of...

Continue Reading
CAI Software Expands Its Manufacturing Throne with PlanetTogether

Updated Category News Views 7

CAI Software's Ambitious Move Who would've guessed, folks? Just another day in the volatile tech landscape, and we see CAI Software splashing the cash to snag PlanetTogether. This isn't just a move to puff up their chest; it's a strategic addition, placing some real weight behind their manufacturing software game. New Horizons with Advanced Planning and Scheduling...

Continue Reading
Artera Expands Its Prostate Test Availability with New License

Updated Category News Views 62

Artera Gains California Lab License to Offer Prostate Test Artera, a leader in artificial intelligence (AI) for cancer diagnostics, recently announced the attainment of its official laboratory license from the California Department of Public Health (CDPH). This important step opens the door for Artera to provide its revolutionary ArteraAI Prostate Test across one of the...

Continue Reading
Bicara Therapeutics Achieves Breakthrough Therapy Milestone for Cancer Treatment

Updated Category News Views 121

Bicara Therapeutics Updates on Financial Results and Business Strategy Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, reports its financial outcomes for the third quarter of 2025 alongside strategic business insights. One of the most noteworthy achievements this quarter is the FDA granting Breakthrough Therapy Designation for...

Continue Reading
ScanTech AI Takes Significant Step with Quarterly Filing Update

Updated Category News Views 179

ScanTech AI's Quarterly Report Filing Details ScanTech AI Systems Inc. is pleased to announce that it has successfully filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC). This filing is a vital step for the company as it aligns with Nasdaq Listing Rule 5250(c)(1), resolving a previous noncompliance issue stemming from a delayed...

Continue Reading